- Home
- AGIO vs CLDX Comparison
AGIO vs CLDX Comparison
Compare AGIO & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGIO | CLDX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2013 | 1995 |
Fundamental Metrics
Financial Performance| Metric | AGIO | CLDX |
|---|---|---|
| Price | $34.45 | $33.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $39.88 | ★ $44.50 |
| AVG Volume (30 Days) | 969.5K | ★ 1.1M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,011,000.00 | $12,743,000.00 |
| Revenue This Year | $74.95 | $111.39 |
| Revenue Next Year | $165.77 | $235.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $22.24 | $17.59 |
| 52 Week High | $46.00 | $34.52 |
Technical Indicators
Market Signals| Indicator | AGIO | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 66.34 | 64.18 |
| Support Level | $26.64 | $24.70 |
| Resistance Level | $36.35 | $34.52 |
| Average True Range (ATR) | 1.38 | 1.56 |
| MACD | 0.08 | 0.11 |
| Stochastic Oscillator | 71.17 | 94.02 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.